The RNA-binding protein IMP2 drives a stromal-Th17 cell circuit in autoimmune neuroinflammation
Open Access
- 8 February 2022
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (3)
Abstract
Stromal cells are emerging as key drivers of autoimmunity, partially because they produce inflammatory chemokines that orchestrate inflammation. Chemokine expression is regulated transcriptionally but also through posttranscriptional mechanisms, the specific drivers of which are still incompletely defined. CCL2 (MCP1) is a multifunctional chemokine that drives myeloid cell recruitment. During experimental autoimmune encephalomyelitis (EAE), an IL-17–driven model of multiple sclerosis, CCL2 produced by lymph node (LN) stromal cells was essential for immunopathology. Here, we showed that Ccl2 mRNA upregulation in human stromal fibroblasts in response to IL-17 required the RNA-binding protein IGF-2 mRNA-binding protein 2 (IGF2BP2, IMP2), which is expressed almost exclusively in nonhematopoietic cells. IMP2 binds directly to CCL2 mRNA, markedly extending its transcript half-life, and is thus required for efficient CCL2 secretion. Consistent with this, Imp2 −/− mice showed reduced CCL2 production in LNs during EAE, causing impairments in monocyte recruitment and Th17 cell polarization. Imp2 –/– mice were fully protected from CNS inflammation. Moreover, deletion of IMP2 after EAE onset was sufficient to mitigate disease severity. These data showed that posttranscriptional control of Ccl2 in stromal cells by IMP2 was required to permit IL-17–driven progression of EAE pathogenesis.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (AI147383)
- National Institute of Allergy and Infectious Diseases (AI148356)
This publication has 58 references indexed in Scilit:
- Posttranscriptional Gene Regulation of IL-17 by the RNA-Binding Protein HuR Is Required for Initiation of Experimental Autoimmune EncephalomyelitisThe Journal of Immunology, 2013
- IMP2 regulates differentiation potentials of mouse neocortical neural precursor cellsGenes to Cells, 2013
- Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patientsEuropean Journal of Neurology, 2011
- mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entryGenes & Development, 2011
- Chemokine Transcripts as Targets of the RNA-Binding Protein HuR in Human Airway EpitheliumThe Journal of Immunology, 2011
- Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis?Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- Transcriptome-wide Identification of RNA-Binding Protein and MicroRNA Target Sites by PAR-CLIPCell, 2010
- Insulin‐like growth factor binding proteins: regulation in chronic active plaques in multiple sclerosis and functional analysis of glial cellsEuropean Journal of Neuroscience, 2006
- IL-17A augments TNF-α–induced IL-6 expression in airway smooth muscle by enhancing mRNA stabilityJournal of Allergy and Clinical Immunology, 2004
- Cc Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune EncephalomyelitisJournal of Experimental Medicine, 2000